A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)

Abroad (travel likely)Recruiting

Conditions

Inflamatory Bowel Disease

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Center of Inflammatory Bowel Disease, Department of Gastroenterology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Contact: Study coordinator (Yan Chen) · chenyan72_72@zju.edu.cn · +86-571-87783777
Contact: Study coordinator (Shurong HU) · hushurong@zju.edu.cn · +86-571-87783777

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease

Inflamatory Bowel Disease · Crohn Disease (CD)

Abroad (travel likely)Recruiting

Shanghai, China

Fecal Microbiome Signature of Multi-Strain Probiotics Supplementation in Children and Adolescents With Inflammatory Bowel Disease

Inflamatory Bowel Disease

Abroad (travel likely)Recruiting

Bern, Switzerland

Renal Dysfunction in Patients With Inflammatory Bowel Disease and the General Population (NEPHRO-IBD)

IBD and Renal Involement · Chronic Kidney Disease · Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis)

Abroad (travel likely)Recruiting

Warsaw, Poland

A Prospective Observational Study on the Efficacy and Safety of Guselkumab in the Treatment of Crohn's Disease Patients Previously Treated With Ustekinumab

Inflamatory Bowel Disease · Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis)

Abroad (travel likely)Recruiting

Hangzhou, China